Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash from Financing Activities: 2019-2025

Historic Cash from Financing Activities for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to $1.2 million.

  • Nurix Therapeutics' Cash from Financing Activities fell 97.48% to $1.2 million in Q3 2025 from the same period last year, while for Aug 2025 it was $203.2 million, marking a year-over-year decrease of 28.76%. This contributed to the annual value of $485.7 million for FY2024, which is 14996.89% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Cash from Financing Activities of $1.2 million as of Q3 2025, which was up 19,150.00% from $6,000 recorded in Q2 2025.
  • In the past 5 years, Nurix Therapeutics' Cash from Financing Activities registered a high of $237.8 million during Q2 2024, and its lowest value of -$135,000 during Q4 2022.
  • Its 3-year average for Cash from Financing Activities is $44.7 million, with a median of $1.5 million in 2023.
  • As far as peak fluctuations go, Nurix Therapeutics' Cash from Financing Activities crashed by 127.00% in 2022, and later skyrocketed by 2,864,485.71% in 2024.
  • Over the past 5 years, Nurix Therapeutics' Cash from Financing Activities (Quarterly) stood at $500,000 in 2021, then slumped by 127.00% to -$135,000 in 2022, then surged by 105.19% to $7,000 in 2023, then surged by 2,864,485.71% to $200.5 million in 2024, then crashed by 97.48% to $1.2 million in 2025.
  • Its Cash from Financing Activities stands at $1.2 million for Q3 2025, versus $6,000 for Q2 2025 and $1.5 million for Q1 2025.